...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: plenty of scenarios being put out there...

"My guess is DM might have been thinking with sales in China of 5 billion at 6% = 300 million in royalties. With two similar deals made, it would amount to around a billion a year, right? "

1. Royalties on 5 billion would be 6% on the first billion, 8% on the next billion, 10% on the last 3 billion.

2. Royalties are from the NET revenue, not gross.

3. Your scenario would require RVX-208 becoming the top selling drug in the world.

Share
New Message
Please login to post a reply